TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11567700

Group type: EXPERIMENTAL
Intervention: 3 MU subcutaneously of recombinant interferon alpha‐2a three times a week for 3 years
Number of subjects: 424

Group type: COMPARATOR
Intervention: Observation alone after surgery
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Surgery plus interferon alpha‐2a
Number of subjects: 424

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 424
Study: 9778073

Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 8152935

Group type: EXPERIMENTAL
Intervention: Prenatal class intervention for clarifying support expectations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confirmation of expectations for mutual support after childbirth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Support received
Number of subjects: 0
Study: 3136954

Group type: EXPERIMENTAL
Intervention: 150 mg t-PA over 6 hours
Number of subjects: 36

Group type: COMPARATOR
Intervention: 100 mg t-PA over 6 hours
Number of subjects: 36
Study: 29954942

Group type: EXPERIMENTAL
Intervention: Western dietary pattern (high intake of high-fat dairy products, processed meat, refined grains, sweets, caloric drinks, and convenience food)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Mediterranean dietary pattern
Number of subjects: 369

Group type: COMPARATOR
Intervention: Prudent dietary pattern
Number of subjects: 369
Study: 29061128

Group type: EXPERIMENTAL
Intervention: 12-week multi-level intervention
Number of subjects: 1000
Study: 24283931

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly or twice weekly for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 0
Study: 23634911

Group type: EXPERIMENTAL
Intervention: prouk-PCI
Number of subjects: 197

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 197
Study: 21374690

Group type: EXPERIMENTAL
Intervention: Previous HBV infection (anti-HBc positive)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Previous HBV infection (anti-HBc alone)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Occult HBV infection (HBV DNA in liver)
Number of subjects: 273

Group type: COMPARATOR
Intervention: HBV DNA in serum
Number of subjects: 273
Study: 18171701

Group type: EXPERIMENTAL
Intervention: Synthetic L-T3 infusion (initial dose: 20 microg/m(2) body surface.d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study: 16829189

Group type: EXPERIMENTAL
Intervention: Drug treatment directed by plasma NTproBNP
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Intensive standardised clinical assessment
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study: 14550448

Group type: EXPERIMENTAL
Intervention: 78 Gy radiotherapy
Number of subjects: 301

Group type: COMPARATOR
Intervention: 70 Gy radiotherapy
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Both 70 Gy and 78 Gy radiotherapy
Number of subjects: 301
Study: 10809983

Group type: EXPERIMENTAL
Intervention: Liquiritin cream applied twice daily for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle cream applied twice daily for 4 weeks
Number of subjects: 20
Study: 8793417

Group type: EXPERIMENTAL
Intervention: Partially hydrogenated fish oil (PHFO‐diet)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Partially hydrogenated soybean oil (PHSO‐diet)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Butterfat (butter‐diet)
Number of subjects: 33

Group type: COMPARATOR
Intervention: All diets (PHFO, PHSO, butter)
Number of subjects: 33
Study: 1290244

Group type: EXPERIMENTAL
Intervention: Oral hydrolytic enzymes
Number of subjects: 19

Group type: COMPARATOR
Intervention: Oral gold salts
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 19
Study: 6207731

Group type: EXPERIMENTAL
Intervention: Topical interferon treatment for adenoviral conjunctivitis
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo treatment for adenoviral conjunctivitis
Number of subjects: 14
Study: 31433462

Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance Exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 30036516

Group type: EXPERIMENTAL
Intervention: Potassium citrate 20 mEq twice daily
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Citric acid 30 mEq twice daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 27004284

Group type: EXPERIMENTAL
Intervention: Platform-switched rough collar (PSRC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Platform-matched smooth collar (PMSC)
Number of subjects: 26
Study: 24472731

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day for 6 months
Number of subjects: 49
Study: 22205670

Group type: COMPARATOR
Intervention: Sodium chlorate 30 mg/kg BW
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium chlorate 60 mg/kg BW
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium chlorate 90 mg/kg BW
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium chlorate 150 mg/kg BW
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium chlorate 300 mg/kg BW
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium chlorate 450 mg/kg BW
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium chlorate 14 mg/kg BW
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium chlorate 42 mg/kg BW
Number of subjects: 16
Study: 21038931

Group type: EXPERIMENTAL
Intervention: Therapist structure with high patient reactance
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Therapist structure with low patient reactance
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Resistance to therapeutic work
Number of subjects: 127
Study: 17332474

Group type: EXPERIMENTAL
Intervention: Meal A (500-ml 15% oil emulsion with 2.5% stable emulsifier)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Meal B (500-ml 15% oil emulsion with 2.5% unstable emulsifier)
Number of subjects: 9
Study: 15025217

Group type: EXPERIMENTAL
Intervention: Fluoridated hydrogen peroxide-based mouthrinse
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 11486635

Group type: EXPERIMENTAL
Intervention: 500 mg aspirin + 50 mg caffeine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 500 mg aspirin + 100 mg caffeine
Number of subjects: 96

Group type: COMPARATOR
Intervention: 0 mg aspirin + 0 mg caffeine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 0 mg aspirin + 50 mg caffeine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 0 mg aspirin + 100 mg caffeine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 500 mg aspirin alone
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 500 mg aspirin + caffeine (any dosage)
Number of subjects: 96
Study: 9923583

Group type: EXPERIMENTAL
Intervention: orlistat 120 mg t.i.d. and ethanol placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: orlistat 120 mg t.i.d. and 40 g ethanol qd on days -1 and 6, and 40 g bid on days 1-5
Number of subjects: 30

Group type: COMPARATOR
Intervention: orlistat placebo tid and 40 g ethanol qd on days -1 and 6, and 40 g b.i.d. on days 1-5
Number of subjects: 30
Study: 7846204

Group type: EXPERIMENTAL
Intervention: Perphenazine decanoate (PD)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Haloperidol decanoate (HD)
Number of subjects: 29
Study: 3288957

Group type: EXPERIMENTAL
Intervention: Weight loss program with caloric restriction and behavior change (n = 26)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Weight loss program with caloric restriction, behavior change, and exercise (n = 25)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Weight loss program with exercise
Number of subjects: 72
Study: 30609278

Group type: EXPERIMENTAL
Intervention: Kinesiotaping plus exercises (n=10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham taping plus exercises (n=10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exercises only (n=10)
Number of subjects: 30
Study: 29624723

Group type: EXPERIMENTAL
Intervention: RT001 (1.8 or 9.0 g/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nondeuterated ethyl linoleate (control)
Number of subjects: 19
Study: 26511775

Group type: EXPERIMENTAL
Intervention: Proficiency-based training on two procedures (appendicectomy followed by salpingectomy)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (training on one procedure - salpingectomy)
Number of subjects: 96
Study: 24660674

Group type: EXPERIMENTAL
Intervention: Coordinated Anxiety Learning and Management (CALM) intervention (CBT, medication, or both)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 336
Study: 22561876

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study: 20632490

Group type: EXPERIMENTAL
Intervention: Autogenous PRP gel with acellular xenogeneic dermal matrix (PRP group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acellular xenogeneic dermal matrix only (control group)
Number of subjects: 30
Study: 17547800

Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.75 mg/kg) intra-arterially before PCI, with a possible supplement of 0.3 mg/kg if procedural time > 90 minutes.
Number of subjects: 160

Group type: COMPARATOR
Intervention: UFH (100 U/kg) intra-arterially before PCI.
Number of subjects: 160
Study: 16339330

Group type: EXPERIMENTAL
Intervention: Exercise activity group (n = 13)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nonexercise control group (n = 15)
Number of subjects: 28
Study: 12228782

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy before planned angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct angioplasty
Number of subjects: 0
Study: 10190761

Group type: EXPERIMENTAL
Intervention: 0.1% naproxen ophthalmic solution
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.2% naproxen ophthalmic solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8544422

Group type: EXPERIMENTAL
Intervention: Captopril test
Number of subjects: 82
Study: 1703608

Group type: EXPERIMENTAL
Intervention: D + HCTZ (dilevalol + hydrochlorothiazide)
Number of subjects: 61

Group type: COMPARATOR
Intervention: C + HCTZ (captopril + hydrochlorothiazide)
Number of subjects: 61
Study: 380340

Group type: EXPERIMENTAL
Intervention: Chewable erythrityl tetranitrate, 10 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31486844

Group type: EXPERIMENTAL
Intervention: Phototherapy mask worn for a minimum of 4 hours after dilating drop instillation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard comfort measures (Control group)
Number of subjects: 51
Study: 27572248

Group type: EXPERIMENTAL
Intervention: L-selenomethionine 166 µg/die
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 26052984

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 14671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14671
Study: 24750973

Group type: EXPERIMENTAL
Intervention: 7-month recall notification
Number of subjects: 10175

Group type: EXPERIMENTAL
Intervention: 12-month reminder notification
Number of subjects: 10175

Group type: EXPERIMENTAL
Intervention: 19-month recall notification
Number of subjects: 10175

Group type: COMPARATOR
Intervention: No notification
Number of subjects: 10175
Study: 22683257

Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (Antox version 1.2, Pharma Nord, Morpeth, UK)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (2 tablets, 3 times/day)
Number of subjects: 70
Study: 19056596

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with supplemental virgin olive oil (VOO)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with supplemental nuts
Number of subjects: 112

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 112
Study: 17634457

Group type: EXPERIMENTAL
Intervention: Combination therapy with an antiplatelet agent and an oral anticoagulant agent (target INR, 2.0 to 3.0)
Number of subjects: 2161

Group type: COMPARATOR
Intervention: Antiplatelet therapy alone
Number of subjects: 2161
Study: 15013302

Group type: COMPARATOR
Intervention: Femoral loop grafts (group I)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Femoral vein transposition (group II)
Number of subjects: 32
Study: 12209041

Group type: COMPARATOR
Intervention: Etoricoxib 5 mg q.d.
Number of subjects: 617

Group type: COMPARATOR
Intervention: Etoricoxib 10 mg q.d.
Number of subjects: 617

Group type: COMPARATOR
Intervention: Etoricoxib 30 mg q.d.
Number of subjects: 617

Group type: COMPARATOR
Intervention: Etoricoxib 60 mg q.d.
Number of subjects: 617

Group type: COMPARATOR
Intervention: Etoricoxib 90 mg q.d.
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Etoricoxib 30 mg q.d. (Part 2)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg q.d. (Part 2)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg q.d. (Part 2)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Diclofenac 50 mg t.i.d. (Part 2)
Number of subjects: 617
Study: 9825197

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gallopamil (100 mg b.i.d.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg b.i.d.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg b.i.d.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gallopamil, Diltiazem, Verapamil
Number of subjects: 18
Study: 7650225

Group type: EXPERIMENTAL
Intervention: Phenylbutyrate (30-minute infusion at 3 dose levels: 600, 1200, and 2000 mg/m2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Phenylbutyrate
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Phenylacetate
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Phenylacetylglutamine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Phenylbutyrate, phenylacetate, and phenylacetylglutamine
Number of subjects: 14
Study: 2655248

Group type: EXPERIMENTAL
Intervention: Truncal vagotomy and drainage (TV)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Selective vagotomy and drainage (SV)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 248

Group type: COMPARATOR
Intervention: All groups (TV, SV, PCV)
Number of subjects: 248
Study: 217894

Group type: EXPERIMENTAL
Intervention: HMG 2250 mg per day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: HMG 3000 mg per day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: HMG 2250 mg and 3000 mg per day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31582355

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg for 30 min every 2 weeks)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Chemotherapy (paclitaxel 100 mg/m2 once per week for 6 weeks or docetaxel 75 mg/m2 every 3 weeks)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 419

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 419
Study: 28973315

Group type: EXPERIMENTAL
Intervention: Ciliary neurotrophic factor treatment
Number of subjects: 67
Study: 26255043

Group type: EXPERIMENTAL
Intervention: Diet low in FODMAPs (n=38)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Traditional IBS diet (n=37)
Number of subjects: 75
Study: 23422332

Group type: EXPERIMENTAL
Intervention: Radix Astragali extract granules (4g bid for 7 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (4g bid for 7 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: ABCB1 3435T mutation allele carriers (placebo phase)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ABCB1 3435CC carriers (RA extract phase)
Number of subjects: 14
Study: 17086091

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg orally at bedtime for 6 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg orally at bedtime for 6 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (12 healthy subjects, no drug administration)
Number of subjects: 47
Study: 15276658

Group type: EXPERIMENTAL
Intervention: Child Beck Depression Inventory (CBDI) administered to all students
Number of subjects: 4143

Group type: EXPERIMENTAL
Intervention: Binary regression analysis
Number of subjects: 4143

Group type: EXPERIMENTAL
Intervention: Symptoms reported by adolescents with depression
Number of subjects: 4143
Study: 11034630

Group type: EXPERIMENTAL
Intervention: Palliative radiation therapy with efficient fractionation schedules
Number of subjects: 0
Study: 8798310

Group type: EXPERIMENTAL
Intervention: Radical cervical diathermy with fulgaration (RCDF)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Large loop excision of the transformation zone (LLETZ)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Both treatments (LLETZ and RCDF)
Number of subjects: 55
Study: 1351183

Group type: EXPERIMENTAL
Intervention: Prophylactic group (n = 58): lactating mothers avoided allergenic foods (milk, egg, fish, and nuts) and avoided feeding their infants these foods and soya, wheat, and orange up to the age of 12 months; acaricidal treatment every 3 months.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (n = 62): unrestricted diet for mothers and infants; no acaricidal treatment.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (n = 62) for asthma prevalence.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (n = 62) for eczema prevalence.
Number of subjects: 120
Study: 3966504

Group type: EXPERIMENTAL
Intervention: Hydrocortisone and timed delivery
Number of subjects: 73

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 73
Study: 31694410

Group type: EXPERIMENTAL
Intervention: Monitoring-guided strategy with VerifyNow P2Y12 test
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: HPR patients
Number of subjects: 1213

Group type: COMPARATOR
Intervention: Non-HPR patients
Number of subjects: 1213
Study: 27666156

Group type: COMPARATOR
Intervention: Steroid group (40mg of triamcinolone acetonide injected into the lateral epicondyle)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Botulinum toxin tend group (20U of botulinum toxin injected into tender points of muscles)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Botulinum toxin epic group (20U of botulinum toxin injection into the lateral epicondyle)
Number of subjects: 26
Study: 25344944

Group type: EXPERIMENTAL
Intervention: Active ABM
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo ABM
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study: 23750778

Group type: EXPERIMENTAL
Intervention: Remote robotic catheter system (RCS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 45
Study: 20716383

Group type: EXPERIMENTAL
Intervention: Health visitor (HV) trained in identification and psychological intervention methods providing care based on cognitive behavioral or person-centered principles.
Number of subjects: 2241

Group type: COMPARATOR
Intervention: Control group receiving care as usual (CAU) from health visitors.
Number of subjects: 2241

Group type: EXPERIMENTAL
Intervention: Intervention group (IG) women with a 6-week EPDS score of 6-11 (subthreshold subgroup).
Number of subjects: 2241

Group type: EXPERIMENTAL
Intervention: Intervention group (IG) women with a 6-week EPDS score of 0-5 (lowest severity subgroup).
Number of subjects: 2241
Study: 19888483

Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mepivacaine
Number of subjects: 42
Study: 16875978

Group type: EXPERIMENTAL
Intervention: NET inhibitor (sibutramine or reboxetine)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 12685057

Group type: EXPERIMENTAL
Intervention: Lower intensities of oral anticoagulation (e.g., INR < 2.0) for long-term secondary prophylaxis of VTE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended-duration LMWH therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel antithrombotic agents
Number of subjects: 0
Study: 10697082

Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated bone grafting
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pure cancellous bone grafting
Number of subjects: 96
Study: 9379369

Group type: EXPERIMENTAL
Intervention: Divide and conquer phacoemulsification (D/C Group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Chip and flip phacoemulsification (C/F Group)
Number of subjects: 41
Study: 1370232

Group type: EXPERIMENTAL
Intervention: Hair growth promoters
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Anagen terminal scalp hairs
Number of subjects: 27

Group type: COMPARATOR
Intervention: Indeterminate (anagen) hairs of balding scalps
Number of subjects: 27

Group type: COMPARATOR
Intervention: Anagen follicles of vellus fore-arm hairs
Number of subjects: 27

Group type: COMPARATOR
Intervention: Telogen scalp hairs
Number of subjects: 27

Group type: COMPARATOR
Intervention: Telogen hairs of balding scalps
Number of subjects: 27

Group type: COMPARATOR
Intervention: Telogen forearm hairs
Number of subjects: 27

Group type: COMPARATOR
Intervention: Completely bald scalps
Number of subjects: 27
Study: 3885472

Group type: EXPERIMENTAL
Intervention: Prostacyclin infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 30
Study: 30389673

Group type: EXPERIMENTAL
Intervention: Intensive weight loss lifestyle intervention based on an energy-restricted Mediterranean diet, physical activity promotion, and behavioral support
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Intensive weight loss lifestyle intervention
Number of subjects: 626
Study: 30596696

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation app 'Headspace' (n = 38) for 10 or 30 days
Number of subjects: 74

Group type: COMPARATOR
Intervention: Wait-list control (n = 36)
Number of subjects: 74
Study: 26208743

Group type: EXPERIMENTAL
Intervention: Individualized nutrition counseling with whey protein supplementation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Individualized nutrition counseling with a nonnutritive placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 24645985

Group type: COMPARATOR
Intervention: Amlodipine 5 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Azelnidipine 16 mg/day
Number of subjects: 32